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Microarray analysis and RNA sequencing of the transcip-
tome in post-mortem human brain tissue is a vital tool in
investigating the complex genetic mechanisms involved in
neurodegenerative and psychiatric disorders (Gilbert et al.
1981; Glanzer et al. 2004; Myers et al. 2007). However,
there are many variables which influence the RNA integrity
in post-mortem human brain tissues which need to be
accounted for such data to be highly reliable (Sajdel-
Sulkowska et al. 1988; Burke et al. 1991; Glasel 1995;
Imbeaud et al. 2005; Schroeder et al. 2006; Birdsill et al.
2010; Durrenberger et al. 2010).
It is important to have a reliable and stable method to
assess the quality of RNA samples generated from precious
heterogeneous tissues, especially from small anatomical
regions, such as the substantia nigra and hypothalamus.
The most widespread measure for estimating the integrity of
RNA samples at present is the RNA Integrity Number (RIN)
as calculated by the Agilent 2100 Bioanalyzer for electro-
phoresis (Agilent Technologies UK Ltd, Edinburgh, UK).
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Abstract
We are building an open-access database of regional human
brain expression designed to allow the genome-wide
assessment of genetic variability on expression. Array and
RNA sequencing technologies make assessment of genome-
wide expression possible. Human brain tissue is a challenging
source for this work because it can only be obtained several
and variable hours post-mortem and after varying agonal
states. These variables alter RNA integrity in a complex
manner. In this report, we assess the effect of post-mortem
delay, agonal state and age on gene expression, and the utility
of pH and RNA integrity number as predictors of gene
expression as measured on 1266 Affymetrix Exon Arrays. We
assessed the accuracy of the array data using QuantiGene,
as an independent non-PCR-based method. These quality
control parameters will allow database users to assess data
accuracy. We report that within the parameters of this study
post-mortem delay, agonal state and age have little impact on
array quality, array data are robust to variable RNA integrity,
and brain pH has only a small effect on array performance.
QuantiGene gave very similar expression profiles as array
data. This study is the first step in our initiative to make
human, regional brain expression freely available.
Keywords: brain pH, microarray validation, post-mortem
human brain, QTL, RIN, RNA.
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The RIN ranges from undetectable to ten, with undetectable
being completely degraded and 10 being the most intact
RNA. The calculation of RIN value is largely based on
ribosomal RNA separation although this measure has been
shown to be inconsistent (Imbeaud et al. 2005; Schroeder
et al. 2006; Sherwood et al. 2011).
We are building a publicly accessible database of regional
human brain expression, the UK Human Brain Expression
Consortium, to allow the assessment of the genetic variability
in gene expression (expression quantitative trait loci, eQTLs)
and splicing (splicing quantitative trait loci, sQTL) as well as
detailed genome-wide expression analysis (Hardy et al.
2009). To that end, we are collecting a large series of
control human brain tissues (originating from 130 individ-
uals) in which we are dissecting 13 different CNS areas:
prefrontal cortex Brodmann areas 9 and 46, parietal cortex
Brodmann areas 3,1, and 2, occipital cortex (OCTX)
Brodmann areas 17, temporal cortex Brodmann areas 21,41
and 42, central white matter (WHMT) below Brodmann
areas 39 and 40, hippocampus, thalamus, hypothalamus,
putamen (PUTM), cerebellum (CRBL), substania nigra,
medulla and spinal cord. From each individual brain, we
isolated DNA for whole genome genotyping analysis and
from each region we isolated RNA for whole transcriptome
exon array analysis. This resulted in a total of 1266 RNA
samples analysed on Affymetrix Exon arrays and represents
by far the largest single CNS expression dataset at present.
For this quality control study, we focused on analysing the
factors that affected the reliability of the RNA samples.
In this study, we assess: (i) the effects of brain bank, age,
gender, cause of death, region, post-mortem delay and brain
pH on RIN-based RNA quality, and, (ii) the effects of RNA
quality on the performance quality of the array experiment,
which was measured by a reliable and widely used param-
eter, present call (%P). %P is the percentage of probe sets
with signal detection above background noise. We examine
the effects of RNA quality on the cDNA preparation and
cRNA production as part of the quality control of the array
experiment, and finally we confirm the reproducibility of
array data using QuantiGene (QG), a novel, PCR-indepen-
dent platform (Canales et al. 2006; Arikawa et al. 2008; Hall
et al. 2011).
Materials and methods
Human post-mortem brain tissue collection and dissection
Brain tissues originating from 101 control Caucasian individuals
were collected by the Medical Research Council (MRC) Sudden
Death Brain and Tissue Bank (Edinburgh, UK; Millar et al.
2007). The bodies were stored refrigerated and were brought up to
the PM suite just prior to the start of the autopsy. Each post-
mortem brain dissection was carried out in the same way. The
whole brain was removed within 15 min of the body as fresh
tissue. The brain was immediately cut into coronal slices and the
various anatomical regions of interest were immediately sampled.
Furthermore, the samples once removed from the coronal slices
were placed in sealed containers which in turn were placed on
cool blocks (chilled to )20C) and stored within an insulated box.
The samples were dissected into various size pieces approximately
250–500 mg and were placed in tubes which were immediately
snap frozen in liquid nitrogen. The post-mortem interval (PMI)
was calculated from the time of death to the time of removal of
the brain from the skull. The total number of samples processed
from this source was 1842 as some CNS regions were not
available. In all cases, control status was confirmed by histology
performed on sections prepared from paraffin embedded brain
blocks and the diagnosis was determined by a consultant
neuropathologist. Detailed phenotypic information is described in
Table 1.
An additional 36 brains originating from neuropathologically
confirmed control Caucasian individuals were collected by the Sun
Health Research Institute (SHRI) an affiliate of Sun Health
Corporation, USA (Beach et al. 2008). In this case, whole brains
were removed as fresh tissue at autopsy and brain coronal slices
were frozen. Anatomical regions of interest were sampled from
brain coronal slices on dry ice. The time interval from the removal
of the brain at the mortuary to the completion of the dissection and
placement of samples within the storage freezer ranged from 2.5 to
4 h. The parietal cortex, hypothalamus and spinal cord regions were
not available for these samples. The total number of samples
processed was 476 as again, some regions were not available from
some brains. Detailed phenotypic information is described in
Table 1.
All samples from both sites had fully informed consent
for retrieval and were authorised for ethically approved scien-
tific investigation (Research Ethics Committee number 10/H0716/
3).
Table 1 Demographics of the samples studied. Values (range, mean) for variables in the cohort from both MRC-UK and SHRI-USA data set
separately and joined. Of note, however, because of the different practices of the two tissue resources, there is no overlap in the PMIs between the
MRC-UK (long PMI) and SHRI-USA (short PMI)
Brain bank Individuals
Sex Age/year Brain pH PMI (h) RIN no.
Male Female Range Mean Range Mean Range Mean Range Mean
MRC-UK 101 78 23 16–83 50.4 5.42–6.31 6.3 28–114 52.2 1–8.5 4
SHRI-USA 36 24 12 53–102 80 NA NA 1–5.5 2.6 1–8 3.6
UK + USA 137 102 35 16–102 59 5.42–6.31 6.3 1–114 43.7 1–8.5 3.85
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Post-mortem determination of brain pH
Brain pH from the MRC-UK samples was recorded from multiple
regions using a Hanna HI8424 hand-held pH meter with a glass
bodied electrode (Fisher Scientific, Loughborough, UK). Consistent
with previous studies, the pH did not vary between different brain
regions (Stan et al. 2006; Monoranu et al. 2009). We therefore used
a single pH value that measured from the lateral ventricle. The
electrode was inserted into the lateral ventricle after the brain was
coronally cut behind the mamillary bodies. The pH is influenced by
that of the tissue comprising the wall of the lateral ventricle and to a
lesser extent by the pH of the remaining CSF fluid within the lateral
ventricle. The pH was not measured in the SHRI-USA samples.
RNA extraction
Total RNA was isolated from human post-mortem brain tissues
based on the single-step method of RNA isolation (Chomczynski
and Sacchi 1987) using the miRNeasy 96 kit (Qiagen, Crawley,
UK). Brain tissues (50–100 mg) were collected and weighed in
RNase-free 96-well plates. A minimum of one extraction was
performed from each tissue sample. All steps were performed on dry
ice prior to the addition of the QIAzol

Reagent. All samples were
homogenised in 4C using the TissueLyser II (Retsch, Castleford,
UK) for 4–5 min at 30 Hz in 800 lL of QIAzol with the addition of
two 3-mm stainless steel beads. In this step, the solution was
homogenised until no large pieces remained.
The homogenised tissue samples were incubated at room
temperature (15–25C) for 5 min. After incubation, 160 lL of
chloroform (CHCl3) (Sigma-Aldrich, Gillingham, UK) was added,
the plates were mixed vigorously using the TissueLyser II for 30 s at
30 Hz. Plates were incubated at room temperature (15–25C) for 7–
10 min. The plates were centrifuged at 6000 g for 45 min at 4C.
The aqueous phase (upper layer, with approximately 60% of the
total volume after the QIAzol was added) was transferred to fresh
RNase-free 96-well plates. RNA was precipitated by adding 800 lL
of 100% ethanol to the aqueous phase (1.5 volume of the aqueous
phase), followed by mixing the samples. The samples were then
transferred into the RNeasy 96-well plates to allow the RNA in the
solution to bind to the membrane by centrifugation.
The plates were centrifuged at 5600 g for 2 min at 21C, and the
supernatantwas discarded. Sampleswerewashed to remove salt traces
and impurities by adding 600 lL of washing buffer and centrifuging
plates for 2 min. Washes were performed 3–4 times. Finally, total
RNA was eluted in 65 lL of pre-heated RNase-free water (50C).
The concentration and purity of each RNA sample was assessed
using the NanoDrop ND-1000 Spectrophotometer V3.3.0. The
concentration of each sample was calculated, together with the ratio
of absorbance at 260 nm/280 nm and 260 nm/230 nm.
After purification all RNA samples were applied to a RNA 6000
Nano-LabChip and analysed using the Agilent 2100 Bioanalyzer
(Agilent Technologies UK Ltd) to obtain the RIN values. RINs and
total RNA electropherograms were calculated by the 2100 Expert
Software (Agilent Technologies UK Ltd). Further assessment of the
RIN was performed by checking each electropherogram visually.
Expression profiling using Affymetrix GeneChip

Human Exon 1.0
ST Arrays
Expression profiling on the Affymetrix GeneChip Human Exon
1.0 ST Arrays (Affymetrix, High Wycombe, UK) was performed at
AROS Applied Biotechnology AS company laboratories (http://
www.arosab.com/).
Total RNA (200 ng) was used as starting material for the cDNA
preparation. First and second strand cDNA synthesis, the in vitro
transcription reaction to generate cRNA and the second round of
cDNA synthesis was performed using the Ambion WT Expression
Kit according to the manufacturer’s instructions. Biotin labelling
was performed using the Terminal Labeling Kit (Affymetrix)
according to the manufacturer’s instructions. Following the in vitro
transcription reaction, the unincorporated nucleotides were removed
using RNeasy columns (Qiagen).
Prior to hybridisation, the fragmented cDNA was heated to 95C
for 5 min and subsequently to 45C for 5 min before loading onto
the Affymetrix Human Exon 1.0 ST array cartridge. The array
cartridge was then incubated for 16 h at 45C at constant rotation
(60 rpm). The washing and staining procedure was performed in the
Affymetrix Fluidics Station 450. The array was exposed to 10
washes in 6· SSPE-T at 250C followed by four washes in 0.5·
SSPE-T at 50C. The biotinylated cRNA was stained with a
streptavidin-phycoerythrin conjugate, final concentration 2 mg/mL
(Affymetrix) in 6· saline sodium phosphate EDTA buffer with
0.01% Tween-20 (SSPE-T) for 30 min at 25C followed by 10
washes in 6· SSPE-T at 25C. This was followed by an antibody
amplification step using normal goat IgG as blocking reagent, final
concentration 0.1 mg/mL (Affymetrix) and biotinylated anti-strep-
tavidin antibody (goat), final concentration 3 mg/mL (Affymetrix).
This was followed by a staining step with a streptavidin–
phycoerythrin conjugate, final concentration 2 mg/mL (Affymetrix,
UK) in 6· SSPE-T for 30 min at 25C and 10 washes in 6· SSPE-T
at 25C. The arrays were scanned at 560 nm using a confocal laser-
scanning microscope (GeneChip Scanner 3000 7G).
Array quality control
The Expression Console (EC) software version 1.1 (Affymetrix)
was used to evaluate the performance quality of the arrays including
the labelling, hybridisation, scanning and background signals by
Probe Set summarisation and CHP file generation using Robust
Multichip Analysis. The quality assessment was performed by
generating different parameters for all the probesets analysed by EC;
%P is the main parameter that is used for the array quality in this
study.
In addition, cDNA and cRNA Agilent 2100 Bioanalyzer profiles
were generated for samples with wide range of RIN numbers (RINs
from 2 to7) to assess the cDNA preparation and cRNA production
nucleotide lengths from RNA samples with different levels of
degradation.
Exon array data analysis
All arrays were pre-processed using Robust Multichip Analysis
quantile normalisation with GC background correction in Partek’s
Genomics Suite v6.6 (Partek Inc., St. Louis, USA) (Lockstone 2011).
After re-mapping the Affymetrix probe sets onto human Ref Seq
build 19 (GRCh37) as documented in the most recent Netaffx
annotation file (HuEx-1_0-st-v2 Probeset Annotations, Release 31),
we restricted analysis to 308,717 probe sets that had a gene
annotation and contained at least three probes with unique
hybridisation. The gene-level expression was calculated for 27 000
genes by the median of probe sets corresponding to each gene.
 2011 The Authors
Journal of Neurochemistry  2011 International Society for Neurochemistry, J. Neurochem. (2011) 119, 275–282
QC parameters for gene expression studies in brain | 277
Array validation using direct RNA quantification with branched
DNA, QuantiGene 2.0 Assay
CRBL, OCTX, PUTM and WHMT samples from 12 individuals
were analysed using the QG platform for validation of exon array
results. We focused on three target genes for validation, leucine-rich
repeat kinase 2 (LRRK2), sodium channel, voltage-gated, type VIII,
alpha subunit (SCN8A), and microtubule-associated protein tau
(MAPT). We selected ribosomal protein, large, P0 and ubiquitin C
as housekeeping genes to normalise the target genes as they showed
relatively low variability in expression levels (i.e. low coefficient of
variation) in all brain regions in our dataset. The approach to the
selection of reference genes is explained in previous studies (de
Jonge et al. 2007; Coulson et al. 2008).In addition, a recent study
confirms the efficiency of using this approach in selecting
housekeeping genes to normalise in different tissues (Chervoneva
et al. 2010). A summary of the QG probes used for analysis of all
five genes is provided in Table 2.
QuantiGene 2.0 Reagent System was used and the protocol in the
QuantiGene 2.0 Reagent System User Manual was followed with
the exception of the substrate step. Lumigen Lumi-Phos Plus and
10% lithium lauryl sulfate was used instead of Lumigen APS-5
substrate. A Biotek ELx 405 select plate washer was used for all of
the wash steps in the assay. The QG 2.0 plates were then read on a
Molecular Devices LMax luminometer with the plate incubator set
to 45C to maintain the temperature of the Lumigen Lumi-Phos
Plus substrate. In total, 13 QG 2.0 plates were run to cover all target
genes and the house keeping genes. Each house keeping gene
ribosomal protein, large, P0 and ubiquitin C was loaded in
duplicates at 12.5 ng/well. In addition, target genes (LRRK2,
SCN8A and MAPT) were loaded in duplicates at 75 ng/well.
Statistical analysis
Linear mixed regression analyses were performed to investigate the
relationship between age, gender, cause of death, region, PMI, pH,
RIN and present call (%P). Statistical analyses were conducted
using Partek Genomics Suite version 6.6 and PASW statistic
version 18 software. We assessed explanatory power in a forwards
stepwise manner, by examining the increase in variation explained
when a new covariate or set of covariates were added to the existing
model, together with a p-value for that increase.
Results
This study involved the analysis of brain tissue originating
from 137 individuals. Since we were not able to obtain all 13
brain regions of interest from each individual, a total of 1302
tissue blocks were available. In the majority of cases (870 of
1302 tissue blocks) multiple RNA extractions were per-
formed, resulting in 2318 RNA samples in total. Each of
these RNA samples was assessed for RNA integrity as
measured by RIN. A single RNA extraction from each tissue
sample was selected on the basis of Agilent 2100 Bioana-
lyzer profile for downstream analysis using the Affymetrix
Exon arrays (Fig. 1).
The effect of age, gender, cause of death, region, PMI and
brain pH on RIN-based RNA quality
We assessed the dependence of RIN values on the other
covariates available to us. Our focus was on the explanatory
power of our available covariates on the RIN for each RNA
extraction (2318 RNA samples). In this study, we assessed
2318 RNA samples. The calculated RIN ranged from 1 to 8.5
with a mean of 3.85 (Table 1). Forty-three per cent of our
samples had RIN values of < 3. We found that 33% of the
variation in RIN was explained by differences among tissue
blocks (adjusted R2 measure), which set an upper limit for the
explanatory power of our covariates, which all act at a
between-tissue-sample level. Sixteen per cent of the variation
in RIN was explained by individual-level differences.
Outside of pH and PMI, which were analysed separately,
the most important covariates were brain region (explained
9.2% of the variation in RIN number, p = 1.7 · 10)42), age
(explained an additional 1.1%, p = 4.1 · 10)05) and cause of
death (explained an additional 1.9%, p = 0.022). Brain bank
and gender together explained an additional 0.4% of the
variation.
pH and PMI were investigated separately, because pH was
not measured in the SHRI-USA dataset and because the
range of PMIs from the two brain banks did not overlap.
pH explained 2.1% of the variation in the RIN number
from the MRC-UK brain bank (p = 1.0 · 10)4) (Fig. 2a).We
note that six individuals had very low pH < 5.90 and when
excluded, the correlation was no longer significant (Fig. 2b).
Table 2 QuantiGene probes used to perform array validation
Gene Catalogue no. Designed to hybridise to
LRRK2 83322 SA-26988 Human LRRK2
SCN8A 83324 SA-17320 Human SCN8A transcript
variants 1 and 2
MAPT 81849 SA-15486 Human MAPT, all six variants
UBC 80041 SA-10061 Human UBC
RPLP0 81152 SA-11148 Human RPLP0 transcript
variants 1 and 2
Fig. 1 Description of the data used in the analysis.
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The effect of PMI on RIN differed between the MRC-UK
and SHRI-USA datasets. There was no significant correlation
between PMI and RIN in the MRC-UK dataset, which had
PMIs ranging from 28 to 114 h. In contrast, PMI explained
8.4% of the variation in RIN in the SHRI-USA dataset
(p = 0.0053), which had PMIs ranging from 1 to 5.5 h.
Longer PMI was associated with a higher RIN in this data
set, a counterintuitive result which might represent con-
founding with some unmeasured variables in the study.
The effects of age, gender, cause of death, region, PMI,
brain pH and RIN-based RNA quality on array performance
(%P, cDNA and cRNA profile)
We assessed the dependence of RNA array performance
quality on RIN-based RNA quality and the other covariates
available to us. A systematic quality control check of the
arrays was performed using Expression Console software.
This software produces a number of array quality measures.
The most reliable and widely used parameter is the present
call (%P) (Tomita et al. 2004; Weis et al. 2007). The percent
present call is the percentage of probe sets with signal
detection above background probe level p -value of £ 0.01.
The range of %P in this study was 1.7–77.3% (mean of
61.4%). Thrity-six per cent of the variation in %P
was explained by individual-level differences (adjusted R2
measure).
Outside of pH and PMI, which for reasons described
previously were analysed separately, the most important
covariates were brain region (explained 12.4% of the
variation in %P, p = 3.6 · 10)53), followed by brain bank
(explained an additional 4.7%, p = 9.6 · 10)6), and then
RIN (explained an additional 2.7%, p = 9.1 · 10)05). Age,
gender, and cause of death together explained an additional
2.2% of the variation. The effect of brain region on %P was
most obvious when comparing CRBL and WHMT. CRBL
showed highest %P (mean = 68%) whereas WHMT showed
the lowest %P (mean = 57.5%) (Fig. 3).
pH explained 12.0% of the variation in %P from the
MRC-UK brain bank (p = 2.3 · 10)9). (Fig. 4). However, as
with RIN, this correlation was highly dependent on the six
individuals with low pH < 5.90. When these samples were
excluded from the analysis no significant correlation was
obtained.
Finally, no significant correlation was found between PMI
and %P, either for the MRC-UK dataset or the SHRI-USA
dataset.
Moreover, no difference was observed in the expected
nucleotide lengths following cDNA preparation (200–400
nt) and cRNA production (ranges from 200 to 2000 nt)
between different samples with different RIN values (as
shown by Agilent Bioanalyser profiles).
(a)
(b)
Fig. 2 (a) Scatter plot for total RNA samples with linear regression line
of RIN numbers for pH. Plot shows the effect of pH on RIN number for
RNA samples isolated from 13 region of control brain tissue. Test
p-values is test p-value = 1.0 · 10)4, r-value = 0.145. Including the
low pH values of < 5.9. (b) Scatter plot for total RNA samples with
linear regression line of RIN numbers for pH. Plot shows the effect of
pH on RIN number for RNA samples isolated from 13 region of
control brain tissue. No significant correlation was obtained with
r-value = 0.0016 and p-value = 0.82. Samples with low pH value of
< 5.9 were excluded.
Fig. 3 Bar chart to show variation in %P by brain region (CRBL,
WHMT).This graph shows the different performance of samples from
specific brain regions on the array. These results are highly significant
p-values (1.3 · 10)24). The heights of the bars represent the mean.
The error bars represent the SEM.
 2011 The Authors
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The reproducibility of array data using QuantiGene, a
PCR-independent platform to confirm expression results
QuantiGene is a technique for mRNA expression quantifi-
cation. Its strength is that it is a non-PCR based technique
that is therefore not subject to the systematic biases that PCR
could create when applied to degraded RNA. This technique
has the potential to be used in place of qRT-PCR (Canales
et al. 2006; Hall et al. 2011).
We validated the exon array results in a subset of 12
individuals by comparing the normalised mRNA expression
level for three genes (LRRK2, SCN8A and MAPT), in four
brain regions (CRBL, OCTX, PUTM and WHMT). We
observed a similar regional pattern of expression across the
two platforms for both high (SCN8A and MAPT) (Fig. 5)
and low expression transcripts in brain (LRRK2) (Fig. 6).
Furthermore, there was an excellent correlation in fold
change (r2 = 0.855) at both the gene and exon expression
levels and signal intensity values (r2 = 0.91) in the four brain
regions we studied.
Discussion
To our knowledge, the UK Human Brain Expression
Consortium data set is the largest control brain microarray
data set generated to date. It is based on the analysis of tissue
samples from 13 different CNS regions originating from 137
individuals and containing 2318 processed samples. The
main goal of this project is to build a large reference database
for eQTL and sQTL analysis.
This study showed considerable variation in RIN values
among RNA samples. Sixty-seven per cent of the variation
resides in differences among extractions from the same
tissue blocks and most of the remaining variation is
unexplained by the available covariate information. We
found that pH is the most important post-mortem factor
influencing RIN-based RNA integrity, a result consistent
with previous studies (Hardy et al. 1985; Mexal et al. 2006;
Chevyreva et al. 2008; Monoranu et al. 2009; Durrenberger
et al. 2010). Samples with very low pH values (ranging
from 5.42 to 5.90) were responsible for the positive
correlation seen between pH and %P (and also RIN).
However, when these low pH samples were removed from
the analysis we no longer observed any significant correla-
tion. This may in part explain contradictory observations
Fig. 4 Scatter plot for total RNA samples with linear regression line of
Present call (%P) for pH. Scatter plot shows that pH significantly
explains 12.0% of the variation in %P (p = 2.3 · 10)9, r = 0.353),
including samples with low pH values. Low pH values are driving the
regression analysis.
Fig. 5 QuantiGene validation of microarray expression data. (a)
SCN8A expression level between different regions. The graph shows
high expression in OCTX compare with other regions. It is clear that
this gene in mostly not expressed in WHMT region (expression level
close to zero) also it presenting large error bar. (b) MAPT, showing
higher expression in OCTX compare with other brain regions. These
results confirm the array data with significant p-values of < 0.01. The
expression level is presenting the mean and the error bars is SEM.
Fig. 6 QuantiGene validation of microarray expression data for
LRRK2 expression level in different regions. The graph shows higher
expression in OCTX compare with other regions. Wilcoxon-signed
rank test was performed and these results confirm the difference
between regions in array data is significant. The expression level is
presenting the median and the stars indicating the significant differ-
ence in expression with p-values of < 0.01. In this case, as LRRK2
expression level was very low, it was unreliable to use SEM and
Wilcoxon’s test was performed using the median values.
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regarding the effect of pH on RNA integrity and sample
performance on arrays (Hardy et al. 1985; Monoranu et al.
2009; Birdsill et al. 2010) and confirms the findings of a
recent, but smaller study on control brain tissue (Tomita
et al. 2004; Sherwood et al. 2011).
We found our array-based expression data to be reliably
validated by the QuantiGene PCR-independent method,
when tested on two high expression genes (MAPT and
SCN8A) and one low expression gene (LRRK2). However,
the performance quality of the array, as defined by %P, was
not profoundly affected by age, gender, region, PMI, RIN
and cause of death. This confirms findings from previous
studies on much smaller sample sizes (Tomita et al. 2004;
Birdsill et al. 2010; Durrenberger et al. 2010). We found that
only 2.7% of the variation in %P was explained by RIN.
Indeed, 80 RNA samples with undetectable RINs performed
well on the arrays with %P values ranging from 45 to 76%.
Thus, we found RIN to be a poor predictor of array quality
performance even at the low end of the RIN scale.
Furthermore, the latter was confirmed since the cDNA and
cRNA length synthesis was not affected by the wide range of
RIN values (from 2 to 7) in our array experiments. The
robust performance of the Affymetrix Exon arrays in the face
of degraded RNA may be due to recent changes to the RNA
amplification process. In keeping with the manufacturer’s
instructions, this was performed using the Ambion WT
Expression kit, which uses both non-polyA and polyA-based
mRNA priming for first strand cDNA synthesis. This meant
that RNA amplification did not require an intact polyA tail.
In addition, increasing the quantity of the starting material of
RNA from 500 to 750 ng improved the array performance.
Through the analysis of this observational study, we
experienced different limitations. For example, we had
expected that cause of death would greatly influence both
RIN-based RNA quality and %P-based array quality, but
cause of death only explained 1.9% of variation in RIN and
we did not find any significant relationship with %P. It may
be that cause of death is an imperfect reflection of the true
medical and drug treatment history of the individual, and that
access to that history, were it available, would reveal other
factors of greater relevance. Likewise, in the range of 28–
114 h PMI did not affect on either RIN or %P, nor could we
see a loss of RIN-based RNA quality over the 1–5 h range. It
remains possible that there may be selective loss of RNA
within an hour because the half-life of some mRNA species
has been reported to be as short as 15 min, while others may
be as long as 22 days depending on the tissue type and
storage conditions (Ross 1995; Barrachina et al. 2006; Bahar
et al. 2007; Beach et al. 2008; Vennemann and Koppel-
kamm 2010). This issue has been studied in detail for a range
of PMIs by Harrison et al. 1995 and confirmed by a more
recent study by Tomita et al. (2004). The same conclusion
was made that PMI had a limited effect on mRNA (Harrison
et al. 1995; Tomita et al. 2004).
Furthermore, there is a possibility that samples with the
shortest PMIs (1–2.5 h) within the SHRI-USA sample set
may originate from those individuals who suffered longer
agonal states prior to death and agonal stress has been shown
to affect gene expression differently in different brain regions
(Li et al. 2007). Other factors may contribute to this such as
intermittent edge effects, especially on small samples during
dissecting and tissue handling procedures.
Finally, we note that our brain samples have been derived
from only two sources: one was a rapid death brain bank with
long post-mortem intervals and the other specialises in
obtaining very short post-mortem intervals. Both brain banks
had separately optimised their protocols to facilitate gene
expression studies and this may limit the generalisability of
these conclusions to tissue collected in other ways.
These results are important for several reasons. Firstly,
they confirm the practical feasibility of using post-mortem
control brain tissue to study the transcriptome of the human
brain by array technology. Secondly, they show that micro-
arrays can give reliable results over a wide range of RIN
numbers (1–8.5) and pH measurements with drop off in array
validity only being observed below brain pH 5.9. Thirdly,
they show that the results from Affymetrix exon arrays are
reproducible by other technologies, making it possible for
database users to use the data generated with confidence.
Furthermore, this study is the first step of an ongoing
multi-regional human brain expression project that has been
established to build an open-access database of identified
genome-wide genetic variability in relation with gene eQTLs
and sQTL as well as for detailed expression analysis (Hardy
et al. 2009). We hope this will move the field forward in our
understanding of the underlying molecular mechanisms of
complex neurological and psychiatric diseases, and will
support the neuroscience community with a resource which
will bring functional insights.
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